在这个试验中，入选标准为年龄大于45岁经历保乳手术的浸润性导管癌的患者。
In this trial, women aged at least 45 years with invasive ductal breast carcinoma undergoing breast-conserving surgery were enrolled.
只有那些没有浸润性癌残留，有完全病理缓解的病人才作为最后的标本分析。
A patient was considered to have had a complete pathologic response if no residual invasive cancer was present on final specimen analysis.
膀胱癌的复发性和浸润性是影响治疗预后的主要原因。
Both invasion and recurrence are the major reasons that limited the therapeutic prognosis of bladder cancer.
应用推荐